BridgeMD
Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”
EU CTIS ID: 2025-524942-87-00
What this study is testing
To assess the prognostic value of ⁶⁸Ga-DOTATATE PET performed just before the 3rd injection of ¹⁷⁷Lu-oxodotreotide on progression-free survival.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years at the time of signing the informed consent
- Well-differentiated grade 2 metastatic gastroenteropancreatic neuroendocrine tumor (Ki-67 ≥ 3% and ≤ 20%)
- Planned treatment with ¹⁷⁷Lu-oxodotreotide
- ⁶⁸Ga-edotreotide PET/CT performed within 2 months prior to the first injection of ¹⁷⁷Lu-oxodotreotide
- Written informed consent obtained
- Affiliated with or beneficiary of a social security system
You likely can't join if
- Pregnant or breastfeeding women
- Protected persons as defined by the French Public Health Code (Articles L1121-5 to L1121-9 and Article L1122-2-III)
- Hypersensitivity reaction or anaphylactic reaction following the administration of the radiopharmaceutical during PET scan no. 1
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.